285 related articles for article (PubMed ID: 20837630)
1. Management of aminoglycosides in the intensive care unit.
Radigan EA; Gilchrist NA; Miller MA
J Intensive Care Med; 2010; 25(6):327-42. PubMed ID: 20837630
[TBL] [Abstract][Full Text] [Related]
2. Do we still need the aminoglycosides?
Durante-Mangoni E; Grammatikos A; Utili R; Falagas ME
Int J Antimicrob Agents; 2009 Mar; 33(3):201-5. PubMed ID: 18976888
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycosides in the intensive care unit: an old drug in a dynamic environment.
Miyagawa CI
New Horiz; 1993 May; 1(2):172-80. PubMed ID: 7922400
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
Croes S; Koop AH; van Gils SA; Neef C
Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306
[TBL] [Abstract][Full Text] [Related]
5. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
Graham AC; Mercier RC; Achusim LE; Pai MP
Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
[TBL] [Abstract][Full Text] [Related]
6. [Aminoglycosides in pediatrics].
Schaad UB
Schweiz Med Wochenschr Suppl; 1996; 76():34S-38S. PubMed ID: 8677417
[TBL] [Abstract][Full Text] [Related]
7. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
8. [Aminoglycoside-induced nephrotoxicity].
Fabrizii V; Thalhammer F; Hörl WH
Wien Klin Wochenschr; 1997 Nov; 109(21):830-5. PubMed ID: 9454436
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
10. Aminoglycosides: a practical review.
Gonzalez LS; Spencer JP
Am Fam Physician; 1998 Nov; 58(8):1811-20. PubMed ID: 9835856
[TBL] [Abstract][Full Text] [Related]
11. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.
Avent ML; Rogers BA; Cheng AC; Paterson DL
Intern Med J; 2011 Jun; 41(6):441-9. PubMed ID: 21309997
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
Heintz BH; Thompson GR; Dager WE
Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
[TBL] [Abstract][Full Text] [Related]
13. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
[TBL] [Abstract][Full Text] [Related]
14. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?
O'Shea S; Duffull S; Johnson DW
Semin Dial; 2009; 22(3):225-30. PubMed ID: 19386073
[TBL] [Abstract][Full Text] [Related]
16. Optimizing use of aminoglycosides in the critically ill.
Rea RS; Capitano B
Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
[TBL] [Abstract][Full Text] [Related]
17. Optimal use of fluoroquinolones in the intensive care unit setting.
Rotschafer JC; Ullman MA; Sullivan CJ
Crit Care Clin; 2011 Jan; 27(1):95-106. PubMed ID: 21144988
[TBL] [Abstract][Full Text] [Related]
18. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Leonard SN; Rybak MJ
Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
[TBL] [Abstract][Full Text] [Related]
19. Aminoglycoside therapy in infectious diseases.
Poulikakos P; Falagas ME
Expert Opin Pharmacother; 2013 Aug; 14(12):1585-97. PubMed ID: 23746121
[TBL] [Abstract][Full Text] [Related]
20. Optimizing aminoglycoside use.
Craig WA
Crit Care Clin; 2011 Jan; 27(1):107-21. PubMed ID: 21144989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
